Nordea Investment Management AB Boosts Stock Position in Hologic, Inc. (NASDAQ:HOLX)
Nordea Investment Management AB boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX – Free Report) by 32.7% in the ...
Morningstar17d
Narrow-Moat Hologic Shifts Smoothly to New Diagnostic Tests
The 2012 acquisition of Gen-Probe dramatically expanded Hologic’s diagnostic capabilities in HPV, chlamydia, gonorrhea, trichomoniasis, and blood screening, and added to ThinPrep’s leading ...
Nasdaq28d
Hologic Trades at 17.62X P/E: Should You Buy, Sell or Hold the Stock?
Hologic is also planning conservatively surrounding ... unlocked by its trailblazing product lines like Panther, ThinPrep liquid-based Pap test, 3D mammography and others. The BV/CV/TV vaginitis ...
Business Insider29d
Cervical cancer recommendations lift ‘minor overhang’ on Hologic, says Leerink
which the firm argues lifts a “minor overhang” on Hologic (HOLX) and the company’s “market-leading” AptimaHPV/ThinPrep cervical cancer screening test. Given co-testing maintained its ...
Hosted on MSN28d
Hologic Trades at 17.62X P/E: Should You Buy, Sell or Hold the Stock?
Hologic HOLX is currently trading at a forward ... unlocked by its trailblazing product lines like Panther, ThinPrep liquid-based Pap test, 3D mammography and others. The BV/CV/TV vaginitis ...
American Association of Individual Investors6d
Which Is a Better Investment, Hologic, Inc. or Insulet Corporation Stock?
Hologic, Inc. engages in the development ... Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test ...
American Association of Individual Investors13d
Which Is a Better Investment, Baxter International Inc. or Hologic, Inc. Stock?
Hologic, Inc. engages in the development ... Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test ...
Yahoo Finance6d
Hologic price target lowered to $76 from $81 at Evercore ISI
Evercore ISI lowered the firm’s price target on Hologic (HOLX) to $76 from $81 and keeps an In Line rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and ...